Skip to main content
European Commission logo print header

Azodicarbonamide: a potential new drug in AISQ


In view of the emergence of resistant strain, even under combination therapy,the search for new active drugs, preferably with a new mechanism of action likeAzodicarbonamide, is of the greatest importance from the public health point ofview. Moreover, due to the costs of such combination therapies, these drugsare not available for the majority of patients and for the populations mostconcerned in the countries in development. The goal of the RTD will be toconduct a Phase II study with Azodicarbonamide following the recommendations ofthe expêrts of the European Community. Based on the optimum dose derived from the Phase II a study, a European study will be conducted in a sufficient numberof HIV infected patients from European clinical centers (Three of them havealready signed an agreement). The economical, ethical and social problemconcerning a new drug in AIDS are reviewed.


Data not available

Call for proposal

Data not available


Hubriphar SA
40,avenue joseph wybran
1070 Bruxelles

See on map

EU contribution
No data